Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

To Find a Coronavirus Vaccine, GlaxoSmithKline Is -2-

10/24/2020 | 12:16am EST

During pandemics, adjuvants are especially valuable because they can increase the potency of vaccines, allowing companies to produce more doses from each batch it manufactures. Glaxo's adjuvant, called AS03, is a combination of vitamin E and liver oil taken from sharks. The company used it to enhance the effectiveness of its vaccine for the H1N1 pandemic in 2009.

To find partners for its adjuvant, Glaxo launched an internal project led by a team of Glaxo drug hunters who looked for anyone working on a key vaccine component -- a protein known as an antigen -- that would cause a person's immune system to build up defenses against the new coronavirus. The hope was that people who got the antigen through vaccination would develop antibodies and perhaps other defenses that could protect against Covid-19.

Glaxo's drug hunters mapped every antigen in the works for Covid-19 using squares on a PowerPoint slide. Every square contained the name of a potential partner, details about the vaccine and a contact person who had spoken with Glaxo. The slide resembled a digital quilt, with some 100 squares.

Some in the quilt approached Glaxo seeking help. Glaxo reached out to others. The campaign was "quite unusual for us," says Mr. Connor. "Going out and offering it to the world was something quite, quite different."

On that first call with Sanofi, Mr. Connor said he remembers telling Mr. Loew: "'There is an opportunity here for us to do something together, which means that we could ultimately go faster for the world and make a difference to the common enemy, which is the virus itself.'"

Within 36 hours, they agreed to create a joint task force that would start exchanging information and planning how to make the partnership work while the companies worked out a formal agreement. "We knew that the world was waiting," Mr. Connor says.

Initial meetings, held by videoconference among employees across multiple time zones, were "slightly awkward" as the rivals turned teammates felt each other out, said Thomas Triomphe, Sanofi's executive vice president for vaccines.

The companies hope to have results from early-stage studies in late November or early December, Mr. Triomphe said. They aim to start a 30,000-person study by the end of the year and to have the vaccine approved in the first half of 2021, he says.

"When you're facing a public-health crisis there is no team with a blue T-shirt and a team with an orange T-shirt. Very quickly, there was only one team," Mr. Triomphe said.

(END) Dow Jones Newswires

10-24-20 0015ET

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.81% 1386 Delayed Quote.-22.09%
LONDON BRENT OIL 0.51% 49.04 Delayed Quote.-27.36%
SANOFI 0.69% 83.6 Real-time Quote.-6.72%
WTI 0.97% 46.11 Delayed Quote.-26.86%
12/03VOLUNTARY AND FREE : Portugal approves COVID-19 vaccination plan
12/03Sanofi to publish COVID-19 vaccine price in development with GSK after Phase ..
12/03GLAXOSMITHKLINE : Downgraded to Neutral by UBS
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
12/01U.S. plans for first COVID vaccines as pandemic deaths surge again
12/01ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions..
12/01GLAXOSMITHKLINE : ViiV Healthcare and the Medicines Patent Pool expand access to..
11/26French health minister confirms vaccination could start by end of year
11/25How will Canada's COVID-19 vaccine program work?
More news
Sales 2020 34 273 M 46 053 M 46 053 M
Net income 2020 4 851 M 6 519 M 6 519 M
Net Debt 2020 22 923 M 30 802 M 30 802 M
P/E ratio 2020 14,1x
Yield 2020 5,77%
Capitalization 68 991 M 92 941 M 92 704 M
EV / Sales 2020 2,68x
EV / Sales 2021 2,55x
Nbr of Employees 99 437
Free-Float 92,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 696,48 GBX
Last Close Price 1 386,00 GBX
Spread / Highest target 69,6%
Spread / Average Target 22,4%
Spread / Lowest Target -20,2%
EPS Revisions
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071